<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: August 26, 1999
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. (the "Company") issued a press release
announcing that the Company appointed Dr. Gerald Wolf as its new Medical
Director and that the Company and Tufts University signed a five-year research
agreement. The Press Release, dated August 26, 1999, is attached as Exhibit 99
hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated August 26, 1999, announcing that
the Company appointed Dr. Gerald Wolf as its new Medical Director and
that the Company and Tufts University signed a five-year research
agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------------
John Smolik, President
Date: August 26, 1999
1
<PAGE>
EXHIBIT INDEX
Exhibit Description
No.
99 Press release of the Company, dated August 26, 1999, announcing
that the Company appointed Dr. Gerald Wolf as its new Medical
Director and that the Company and Tufts University signed a
five-year research agreement.
2
<PAGE>
Exhibit 99
FOR IMMEDIATE RELEASE
Media Contact: Hilary Kaye or Joan Murray
Hilary Kaye Associates
(714) 426-0444 (PST)
or [email protected]
Investor Relations Contact: Craig Dickson
Financial Relations Board
(312) 266-7800 (CST)
Tufts University Contact: Margaret Combs
(508) 839-7910
PHOTOGEN TECHNOLOGIES APPOINTS DR. GERALD WOLF
MEDICAL DIRECTOR; CANCER STUDIES TO BE FOCUS OF FIVE-YEAR
AGREEMENT WITH TUFTS UNIVERSITY
(Knoxville, TN, Aug. 26, 1999) - Photogen Technologies, Inc. (OTC BB: PHGN)
today announced the appointment of Gerald Wolf, Ph.D., M.D., a leading
researcher in the field of interventional radiology, as its Medical Director and
a five-year agreement with Tufts University School of Veterinary Medicine to
develop new cancer treatments.
Photogen also stated that under Dr. Wolf's direction, the Company's oncology
program will be expanded to add breast cancer to its lung and prostate cancer
treatment studies.
Dr. Wolf, previously a professor at Harvard Medical School, is the former
Director of the Center for Imaging and Pharmaceutical Research at Massachusetts
General Hospital. Dr. Wolf's primary research focus has been non-invasive and
minimally invasive cancer treatments. Most recently, Dr. Wolf has been working
with Photogen to develop a non-invasive photodynamic treatment for prostate and
lung cancer.
Dr. Wolf will transfer his group to Tufts, a leading veterinary school with
outstanding animal facilities that treats animals with naturally occurring
cancers. He is Professor Emeritus at Harvard University and will also become a
Research Professor at Tufts University School of Veterinary Medicine. As part of
the new alliance, Photogen will provide Tufts with a new Picker
<PAGE>
CT Scanner (computed tomography) with highly sophisticated imaging
capabilities for Dr. Wolf's cancer program.
"These are very significant announcements for Photogen," commented John Smolik,
Photogen's president and chief executive officer. "Dr. Wolf is uniquely
qualified to lead Photogen's efforts in the development of photodynamic
technologies for non-invasive or minimally invasive cancer treatments. Dr. Wolf
and his team will bring the technical expertise, leadership and medical
experience to drive our early experimental results through clinical trials and
into successful new cancer treatments for humans and animals."
Dr. Wolf is a leading investigator whose research utilizes modern imaging
technology, such as computed tomography (CT), ultrasound or magnetic resonance
imaging (MRI), along with enhancing agents such as photoactive drugs, to guide
minimally invasive treatments of cancer. He is the author of numerous articles
in peer-reviewed journals, and is an inventor with respect to five world-wide
patents and several patent applications under review.
"I am very pleased to assume the position of Medical Director, a logical next
step in my relationship with Photogen. The Company is involved in exciting
research on many fronts and I look forward to helping move this research from
pre-clinical to clinical studies and to eventual human use," Dr. Wolf said.
In pre-clinical studies, Dr. Wolf and Photogen have demonstrated that a widely
used compound selectively binds with tumor tissue and is retained in the tumor
for many days. This provides improved contrast and thus clearly shows tumor
margins during a CT scan.
"The relationship with Tufts is expected to bring significant value," commented
Dr. Wolf. "We will be able to help treat animals with naturally occurring
cancer, an ideal situation for Photogen and Tufts. Our results will help us
plan more effective clinical trials for humans with cancers or tumors surrounded
by normal tissues that must be preserved. It's a true win-win situation."
Dr. Philip Kosch, dean of the Tufts University School of Veterinary Medicine,
said, "This five-year agreement with Photogen Technologies represents a
wonderful opportunity to advance both human and animal health."
Dr. David Ruslander, veterinary radiation oncologist at Tufts, added, "We are
very excited to be working with Dr. Wolf and Photogen on these projects because
the results eventually can benefit both human and animal cancer patients. New
state-of-the-art computed tomography capabilities and a three-dimensional
radiation treatment planning system will be added to the Foster Hospital for
Small Animals at Tufts, which will benefit our veterinary patients."
Smolik commented, "Although we have a great deal of scientific and regulatory
work to do before we have a marketable product, our recent and ongoing
discoveries may ultimately
<PAGE>
significantly reduce treatment costs and greatly improve the quality of life
for cancer patients." He added that breast, lung and prostate cancers are
among the most prevalent cancers in the United States today.
Tufts University School of Veterinary Medicine is New England's only veterinary
school. It has the largest residency-training program in veterinary emergency
and critical care in the United States. The School's Center for Animals and
Public Policy offers the country's only graduate degree in the field of
human/animal relationships and related public policies. It is world-renowned for
its signature programs in wildlife medicine and international veterinary
medicine.
Photogen Technologies, Inc. is a development-stage company focused on creating
photodynamic-related health-care products based on its proprietary multi-photon
excitation and other related technologies. The company has discovered new
methods for using light energy from lasers and x-rays to activate photoactive
agents within deep tissue sufficient to produce a range of beneficial
therapeutic and diagnostic outcomes. These technologies involve methods,
materials and devices that may be used to produce light and photoactive agents
that will destroy diseased cells, remove tissue or identify and diagnose
disease. Photogen's proprietary technology is covered under existing U.S.
patents and additional pending applications in the U.S. and worldwide. The
company has no products or operating revenues at this time.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor provision
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks, which may cause the company's actual
results in the future to differ materially from expected results. These risks
and uncertainties include: the ability of the company to develop a product and
obtain regulatory approval for its use; the ability of the company to
successfully market and sell any products and equipment; the company's ability
to manufacture products in sufficient quantities; the company's ability to
maintain intellectual property protection for its proprietary products, to
defend its existing intellectual property rights from challenges by third
parties, and to avoid infringing intellectual property rights of third parties;
unforeseen operating risks; the company's ability to secure collaborative
agreements with third parties for various research, development, manufacturing,
marketing and other functions; competition; risks associated with the dependence
on manufacturers of the company's proposed products; the availability of capital
to finance planned activities; and the extent to which the clinicians performing
the procedures are able to obtain third-party reimbursement. These risks are
qualified in their entirety by cautionary language and risk factors set forth in
the company's filings with the Securities and Exchange Commission.
